GlobalData

The healthcare industry reported 91 VC deals worth $3.3 billion in November 2020

The country’s small size, dense population and strong healthcare infrastructure should mean distribution of the vaccine with cold…

Between 2017 and 2019, the number of clinical trials initiated for PD-1/PD-L1 targeted combination therapies increased…

If Provention Bio’s rolling Biologic License Application (BLA) submission to the FDA for teplizumab is approved, teplizumab will…

In preclinical testing on animal models, GMA301 showed improved efficacy in lowering right ventricular pressure and hypertrophy,…

The NASH market will undergo a very rapid growth, at a compound annual growth rate (CAGR) of 68.8 per cent from 2019 to 2029

In modern history, no vaccine has ever been considered as essential to restoring normality to our way of life as these first mRNA…

Vaccine developers are selecting manufacturers that are closer to their homes, which could be due to storage or manufacturing…

Most contract manufacturing service agreements are for recombinant vector vaccines, followed by subunit vaccines

T2D market growth factors are increasing diagnosed prevalence of disease and the emergence of novel pipeline agents